Peptide guides12

BPC-157: Benefits, Dosage, Side Effects & 2026 Guide

Published May 21, 2026Updated November 5, 2026
Quick Brief

BPC-157 benefits, mechanism, dosage, side effects, TB-500 stacking, FDA 2026 reclassification, and where to buy legally in 2026.

BPC-157: Benefits, Dosage, Side Effects & 2026 Guide
BPC-157 (10mg)

Procurement

BPC-157 (10mg)

In StockShips from USA
$24.50$49.00
Get BPC-157 (10mg)

BPC-157 (Body Protection Compound-157, also written BPC157) is a synthetic 15-amino-acid peptide copied from a protein in human gastric juice, used for tendon, joint and gut healing. As of November 2026 it has no FDA approval, but an October 28, 2026 HHS policy lets licensed 503A pharmacies compound single-ingredient BPC-157 with a prescription.

BPC-157 is the most widely used healing peptide in the world. Not the most studied in clinical trials, those are GLP-1 drugs, but the most used by people actually trying to fix something: a torn tendon, a wrecked gut, a joint that won't stop hurting.

Last Updated November 5, 2026
15 Amino acid peptide chain (pentadecapeptide)
Gastric Derived from human gastric juice protein
250-500 mcg Typical daily dose (subcutaneous)
1-2 weeks When most people notice first improvements
<30 min Elimination half-life in published pharmacokinetic data (He 2022)

🔑 Key Takeaways

  • Status as of November 2026: the FDA's advisory committee voted 8–6 (1 abstention) for BPC-157 on July 23, 2026, and under HHS's October 28, 2026 policy, licensed 503A pharmacies may compound single-ingredient BPC-157 on a prescription while the policy stands. It still has no FDA approval
  • BPC-157 (Body Protection Compound-157) is a 15-amino acid peptide fragment derived from a protein naturally found in human gastric juice. It accelerates healing across tendons, ligaments, muscles, gut lining, nerves, and skin
  • The primary mechanism is angiogenesis: BPC-157 builds new blood vessels at injury sites, dramatically increasing oxygen and nutrient delivery to damaged tissue. It also upregulates growth factors and modulates nitric oxide signaling
  • Gut healing is the most biologically direct application because BPC-157 originates from the gastric system. NSAID damage, leaky gut, IBS symptoms, and post-antibiotic gut issues respond fastest
  • Tendon and ligament repair is the most common use case. Injuries that have persisted for months often begin improving within 1 to 2 weeks
  • BPC-157 peptide is available as injectable (subcutaneous) and oral capsules. Injectable provides systemic benefits. Oral delivers directly to the GI tract for gut-specific goals
  • Side effects are minimal: injection site redness, occasional nausea. No serious adverse events have been widely reported at standard doses
  • Often stacked with TB-500 (the Wolverine Stack) for amplified healing, covering both blood vessel formation and cell migration

This is the full picture of BPC-157: what it is, how it works, every documented benefit, dosing, side effects, stacking, and how to use it.

BPC-157 FDA Status in 2026: Reclassification & What Changed

The legal and regulatory landscape for BPC-157 shifted meaningfully in 2026. If you're reading anything written before October 28, 2026, the rules have changed: the July advisory vote is over, and HHS has since issued a compounding policy.

BPC-157 regulatory timeline (as of November 2026):

  • September 29, 2023: FDA placed BPC-157 in Category 2 of its 503A bulk-substance interim policy (substances that "may present significant safety risks"), which shut off pharmacy compounding (FDA Category 2 list, 2024 archive).
  • April 2026: The nominations were withdrawn and BPC-157 left Category 2. FDA's page (content current as of April 22, 2026) now lists it under "nominated but withdrawn" (FDA). Leaving Category 2 did not by itself make it legal to compound.
  • July 23, 2026: FDA's Pharmacy Compounding Advisory Committee (PCAC) voted 8–6 with 1 abstention to recommend adding BPC-157 to the 503A bulks list, against the recommendation of FDA staff. The vote is advisory (RAPS; our PCAC vote recap).
  • October 28, 2026: HHS issued an interim enforcement-discretion policy, published in the Federal Register on October 30, 2026 (91 FR 68526). HHS will not take action against state-licensed pharmacies, federal facilities or licensed physicians that compound BPC-157 acetate for subcutaneous, intramuscular, oral or topical use, with a patient-specific prescription and a certificate of analysis from an FDA-registered manufacturer (Baker Donelson summary; our HHS peptide policy explainer).
  • Blends are excluded: the policy covers only products with a single active ingredient, so BPC-157 + TB-500 (Wolverine), GLOW and KLOW blends are not covered.
  • Still pending: FDA rulemaking to place BPC-157 on the 503A bulks list. BPC-157 has no FDA approval for any use, and enforcement discretion is not approval.
  • Peptide vendors (Ascension, others) remain the main supply channel for people buying without a prescription. Their vials are labelled for laboratory use only, and the HHS policy does not cover them: it applies to pharmacies and physicians, not online sellers.
  • WADA: BPC-157 is on the World Anti-Doping Agency Prohibited List (Section S2, peptide hormones). Athletes in tested sport should not use it under any route.

Practical translation: for anyone outside competitive testing, BPC-157 is more accessible in November 2026 than at any point since 2023. A doctor can prescribe single-ingredient BPC-157 and a 503A pharmacy can fill it, but the policy is interim and HHS says it can revisit it if a safety or quality problem appears. For current vendor verification and compounded-route status see our BPC-157 legal sourcing guide and the broader FDA AdCom peptide restrictions briefing.

What Is BPC-157?

A fragment of a protein your stomach already makes.

BPC-157 stands for Body Protection Compound-157. It's a synthetic version of a 15-amino acid sequence found in human gastric juice, the digestive fluid your stomach produces. The natural protein (called BPC) plays a role in protecting and repairing the GI tract. BPC-157 is a stable fragment of that protein, engineered to survive longer and produce stronger effects than the natural version.

The peptide was first characterized in the 1990s. Since then, it has been studied in hundreds of models across tissue types: tendons, ligaments, muscles, bones, gut lining, blood vessels, nerves, and skin. No human clinical trials have reached Phase 3 (a common criticism), but the breadth of consistent data across models, combined with extensive community use, has made it the most popular healing peptide available.

BPC-157 has no FDA approval for any indication. Since October 28, 2026 it can be compounded by 503A pharmacies with a prescription under an interim HHS policy, and it is also sold by peptide suppliers. FDA has not yet completed the rulemaking that would add it to the 503A bulks list.

BPC-157 Human Evidence So Far

Three small studies. That's the whole human record.

Every human study of BPC-157 published so far is a small pilot or chart review without a control group, and all three share the same lead author working in private clinics. A 2026 systematic review found these 3 studies, 30 people in total, and rated the certainty of evidence "very low" (Poolton et al., Acta Orthop Belg 2026, PMID 42885452).

Human evidence at a glance
Study
Who
What was given
What it found
Knee pain chart review (Lee & Padgett, 2021, PMID 34324435)
17 patients, 16 reached by phone
Intra-articular BPC-157 (12 alone, 4 with thymosin beta-4)
14 of 16 (87.5%) reported relief; 11 of 12 on BPC-157 alone. Retrospective, no control group, no imaging
Interstitial cystitis pilot (Lee et al., 2024, PMID 39325560)
12 women who had not responded to pentosan polysulfate
10 mg BPC-157 injected around the bladder in one cystoscopy
10 of 12 reported complete symptom resolution, 2 reported 80%; no adverse events reported. No control group, self-rated
IV safety pilot (Lee & Burgess, 2025, PMID 40131143)
2 adults who had used IV BPC-157 before
10 mg IV on day 1, 20 mg IV on day 2
No change in heart, liver, kidney, thyroid or glucose markers; no side effects reported. Two people only
Knee pain chart review (Lee & Padgett, 2021, PMID 34324435)
Who
17 patients, 16 reached by phone
What was given
Intra-articular BPC-157 (12 alone, 4 with thymosin beta-4)
What it found
14 of 16 (87.5%) reported relief; 11 of 12 on BPC-157 alone. Retrospective, no control group, no imaging
Interstitial cystitis pilot (Lee et al., 2024, PMID 39325560)
Who
12 women who had not responded to pentosan polysulfate
What was given
10 mg BPC-157 injected around the bladder in one cystoscopy
What it found
10 of 12 reported complete symptom resolution, 2 reported 80%; no adverse events reported. No control group, self-rated
IV safety pilot (Lee & Burgess, 2025, PMID 40131143)
Who
2 adults who had used IV BPC-157 before
What was given
10 mg IV on day 1, 20 mg IV on day 2
What it found
No change in heart, liver, kidney, thyroid or glucose markers; no side effects reported. Two people only

What this means for you: the reports are encouraging and no serious harm has been recorded, but 30 people without a comparison group cannot show that BPC-157 works or that it is safe long term. The doses above are the doses those studies used, not a protocol to copy.

How BPC-157 Works

Four mechanisms, all running simultaneously.

Most healing compounds target one pathway. BPC-157 operates across several, which explains why it shows results across so many tissue types:

  • Angiogenesis: BPC-157 stimulates new blood vessel formation at injury sites by upregulating VEGF (vascular endothelial growth factor). More blood supply means more oxygen, more nutrients, and faster clearance of inflammatory waste. This is the primary mechanism behind accelerated healing.
  • Growth factor upregulation: Beyond VEGF, BPC-157 increases activity of EGF (epidermal growth factor), FGF (fibroblast growth factor), and other repair-signaling molecules. These drive tissue regeneration at the cellular level.
  • Nitric oxide modulation: BPC-157 interacts with the nitric oxide system, which regulates blood flow, inflammation, and neurotransmitter activity. This pathway connects to both its cardiovascular and neuroprotective effects.
  • Anti-inflammatory signaling: Reduces pro-inflammatory cytokines at injury sites without the systemic immunosuppression of NSAIDs or corticosteroids. The inflammation goes down, but your immune system stays functional.

The combination is why BPC-157 doesn't just help one tissue type. It supports the entire repair infrastructure.

BPC-157 Benefits

Every documented effect, organized by strength of evidence and user experience.

Tendon and Ligament Healing

The most common reason people use BPC-157.

Tendons heal slowly because they have poor blood supply compared to muscles. BPC-157 directly addresses this by building new vasculature into the damaged tissue. Studies show accelerated healing of Achilles tendon injuries, MCL tears, rotator cuff damage, and patellar tendinopathy.

What users consistently report: tendon pain that has lingered for months begins improving within 1 to 2 weeks. Full resolution typically takes 4 to 8 weeks. The improvement isn't just pain masking. The tissue is structurally repairing. For dosing details, see the BPC-157 dosage page.

Gut Healing

The benefit with the strongest biological logic.

BPC-157 comes from the gut. It's a fragment of a gastric protection protein. Its effects on the GI lining are the most directly supported of any application:

  • Heals NSAID-induced stomach and intestinal ulcers (ibuprofen, naproxen, aspirin damage)
  • Repairs intestinal permeability ("leaky gut") by restoring tight junction integrity
  • Reduces GI inflammation relevant to IBS, IBD-related symptoms, and post-antibiotic dysbiosis
  • Protects against alcohol-induced gastric lesions
  • Accelerates healing of inflammatory bowel damage

Gut benefits appear fastest. Reduced bloating, less post-meal discomfort, and improved regularity often within the first week. This is also why oral BPC-157 capsules are popular for gut-specific goals.

Muscle Recovery

Faster repair between training sessions.

BPC-157 accelerates muscle fiber regeneration through the same angiogenic and growth factor mechanisms that help tendons. For athletes and anyone training hard, this means less soreness, faster recovery between sessions, and the ability to maintain volume through minor strains. Crushed muscle tissue in studies showed significantly faster regeneration with BPC-157 compared to controls.

Joint Pain and Inflammation

Even people using BPC-157 for a specific injury report improvement in other joints. The systemic anti-inflammatory effect reduces inflammatory cytokines throughout the body. Particularly relevant for people with multiple joint complaints or chronic inflammatory conditions.

Nerve Healing

One of the less discussed applications.

BPC-157 shows neuroprotective effects and accelerated peripheral nerve regeneration. Studies demonstrate improved recovery from nerve crush injuries and protection against neurotoxic damage. People with neuropathy or nerve entrapment sometimes report improvement. The peptides for nerve damage page covers this in detail.

Wound Healing and Skin Repair

Cuts, surgical incisions, and burns show faster closure rates with BPC-157. The improved blood supply reduces infection risk. Some users report less scarring from injuries sustained while on a BPC-157 protocol, likely from better-organized collagen deposition.

Cardiovascular Protection

BPC-157 has shown protective effects on the cardiovascular system: preventing arrhythmias, protecting against certain types of cardiac damage, and improving endothelial function. The nitric oxide modulation pathway is central here. Not a cardiac drug, but an added systemic benefit.

Neuroprotection and Brain Injury Recovery

One of the most underrated benefit categories.

Animal studies show BPC-157 protects dopaminergic neurons against MPTP-induced damage (a model used for Parkinson's research) and accelerates recovery after traumatic brain injury. The mechanism appears to involve preserving nitric oxide signaling and reducing neuroinflammation in damaged brain tissue. User reports for post-concussion symptoms and persistent cognitive fog after head impacts are common, though human trials remain absent.

Mental Health: Anxiety and Depression via the Gut–Brain Axis

BPC-157's effects on mood emerge from its primary GI mechanism: a healthier gut produces healthier serotonin and dopamine signaling. Animal models show clear anxiolytic and antidepressant-like effects, especially in stress-induced models. Many users with chronic gut issues report unexpected mood lift alongside the physical healing. For the deeper protocol context see our BPC-157 for anxiety and depression guide.

Gastric Protection: NSAIDs, Alcohol, and Corticosteroids

BPC-157 protects the stomach lining against the most common chemical insults: chronic NSAID use, alcohol exposure, and corticosteroid therapy. It's not just symptom relief; the rat model literature shows BPC-157 prevents the actual erosion and ulceration these drugs cause. For people who need to take NSAIDs long-term for joint pain (or are stuck on a corticosteroid course), this protective effect is one of the most well-replicated findings in the entire BPC-157 literature.

BPC-157 Results Timeline: What to Expect Week by Week

Results scale with the type of injury and the dose, but the typical progression is consistent enough to map out. Use this as a baseline expectation, not a guarantee.

Phase
What you'll notice
What's happening biologically
Week 1–2
Mild reduction in baseline inflammation. Sore tendons feel slightly less sharp. Gut symptoms (bloating, reflux) start easing.
Initial NO modulation and anti-inflammatory effect. Angiogenesis hasn't kicked in yet.
Week 2–4
Joint and tendon pain that's been there for months starts measurably improving. Range of motion expands. Sleep often improves.
New microvasculature reaches damaged tissue. Growth factor cascades upregulated.
Week 4–8
Soft-tissue injuries that "wouldn't heal" begin closing. Tendinopathy resolves. Gut inflammation drops further. Energy/mood lifts.
Active tissue remodeling. Collagen synthesis accelerates. Gut–brain axis stabilizes.
Week 8–12
Full resolution of most acute injuries. Chronic conditions reach a new baseline. Decision point: continue, cycle off, or maintain at lower dose.
Repair plateau. Tissue is structurally remodeled, not just masked.

For documented before/after cases from real users, see our BPC-157 before and after results gallery.

BPC-157 Dosage

Two routes, different use cases.

Subcutaneous Injection (most common)

Protocol
Dose
Frequency
Duration
Standard healing
250-500 mcg
Once daily
4-8 weeks
Acute injury
500 mcg
Twice daily
2-4 weeks
Maintenance / prevention
250 mcg
Once daily
4 weeks on, 2-4 weeks off
Standard healing
Dose
250-500 mcg
Frequency
Once daily
Duration
4-8 weeks
Acute injury
Dose
500 mcg
Frequency
Twice daily
Duration
2-4 weeks
Maintenance / prevention
Dose
250 mcg
Frequency
Once daily
Duration
4 weeks on, 2-4 weeks off

Inject into abdominal fat (subcutaneous). Systemic distribution means you don't need to inject at the injury site. Use the reconstitution calculator to determine how much bacteriostatic water to add for your dose.

Once daily or twice daily? Two conventions, no trial. You will see two community conventions for BPC-157, and neither comes from a human trial. This page lists 250–500 mcg once daily; our BPC-157 dosage guide and BPC-157 dosage chart use 250 mcg twice daily (500 mcg a day) as the standard. The split schedule is built around the short half-life: under 30 minutes in published pharmacokinetic data (He et al., Front Pharmacol 2022, PMID 36588717). The daily total is similar either way. The same goes for injection site: the dosage guide favours injecting near the injury, this page the abdomen, and no human study has compared the two.

Oral Capsules

500-1,000 mcg daily for gut-specific goals. Lower systemic bioavailability than injection but delivers the peptide directly to the GI tract. Best for IBS, leaky gut, NSAID recovery, and ongoing gut maintenance. No injection required.

Full protocols are covered on the BPC-157 dosage page.

BPC-157 Side Effects

Minimal and predictable.

BPC-157 has one of the most favorable safety profiles in the peptide space:

  • Injection site redness: Most common, mild, resolves within hours. Rotate sites.
  • Nausea: Occasional, usually from injecting on an empty stomach. Eating beforehand helps.
  • Mild dizziness: Uncommon, typically at higher doses only.
  • Fatigue: Rare, first few days of a cycle.

No serious adverse events have been widely reported at standard doses. The main theoretical concern: BPC-157's angiogenic activity means people with active cancer should consult their oncologist before use, as promoting new blood vessel formation could theoretically support tumor vascularization. No such cases have been documented, but the mechanism warrants caution.

Full side effect breakdown on the BPC-157 side effects page.

BPC-157 + TB-500: The Wolverine Stack

The most popular peptide stack for a reason.

BPC-157 and TB-500 target different bottlenecks in healing:

Peptide
Primary mechanism
What it does
BPC-157
Angiogenesis
Builds new blood vessels to the injury site
TB-500
Cell migration
Moves repair cells to where they're needed

BPC-157 creates the infrastructure. TB-500 brings the workers. Together, they cover the two biggest bottlenecks: blood supply and cell delivery. The Wolverine Stack from Ascension Peptides combines both in one product. The Wolverine Stack dosage page covers the combined protocol.

One caution on "together is better." The only head-to-head test so far, a 2026 Achilles tendon-repair study in 32 lab animals, found TB-500 alone gave the clearest gains in tendon strength and structure, and the combination added no benefit over either peptide alone (Biçer et al., Jt Dis Relat Surg 2026, PMID 42542926). Blends are also outside the October 2026 HHS compounding policy, which covers single-ingredient products only.

For broader healing coverage that also includes anti-inflammatory and skin benefits, the KLOW blend adds GHK-Cu and KPV to the BPC-157 + TB-500 foundation.

BPC-157 vs Other Healing Peptides

BPC-157 is the most popular healing peptide, but it's not the only one. Here's how it stacks up against the alternatives people most often consider.

Peptide
Mechanism
Common dose
Best for
Time to results
Angiogenesis, NO modulation, growth factor upregulation
250–500 mcg once daily
Tendons, ligaments, gut, joint pain
1–4 weeks
Actin regulation, cell migration, anti-inflammatory
2–5 mg twice weekly
Soft tissue injuries, systemic recovery
2–6 weeks
Copper transport, skin remodeling, anti-inflammatory
1–3 mg twice weekly (SubQ)
Skin, wound healing, hair
3–8 weeks
KPV
Anti-inflammatory tripeptide, melanocortin pathway
250–500 mcg daily
Gut inflammation, skin, autoimmune
2–6 weeks
PDA (Pentadeca-Arginate)
Modified BPC-157 analog, similar pathway
500 mcg twice daily
Same as BPC-157, marketed as the "legal" version
1–4 weeks
Mechanism
Angiogenesis, NO modulation, growth factor upregulation
Common dose
250–500 mcg once daily
Best for
Tendons, ligaments, gut, joint pain
Time to results
1–4 weeks
Mechanism
Actin regulation, cell migration, anti-inflammatory
Common dose
2–5 mg twice weekly
Best for
Soft tissue injuries, systemic recovery
Time to results
2–6 weeks
Mechanism
Copper transport, skin remodeling, anti-inflammatory
Common dose
1–3 mg twice weekly (SubQ)
Best for
Skin, wound healing, hair
Time to results
3–8 weeks
KPV
Mechanism
Anti-inflammatory tripeptide, melanocortin pathway
Common dose
250–500 mcg daily
Best for
Gut inflammation, skin, autoimmune
Time to results
2–6 weeks
PDA (Pentadeca-Arginate)
Mechanism
Modified BPC-157 analog, similar pathway
Common dose
500 mcg twice daily
Best for
Same as BPC-157, marketed as the "legal" version
Time to results
1–4 weeks

Most BPC-157 users eventually stack it with TB-500 (see the Wolverine Stack below) once the basics are working. For a fuller comparison of injury-recovery peptides see our guide on BPC-157 alternatives.

Where to Buy BPC-157

Three routes, different tradeoffs.

Compounding pharmacy (prescription required): The most regulated route. Requires a prescription from a physician or telehealth platform. Pharmacies compound BPC-157 under USP 797 sterile standards. Quality is verified but cost is higher. Since October 28, 2026 this route is covered by the HHS enforcement-discretion policy for single-ingredient BPC-157 by injection, by mouth or on the skin.

Licensed peptide supplier: Companies like Ascension Peptides offer BPC-157 with independent third-party testing and certificates of analysis. Available without a traditional prescription in most cases. Verify CoA documentation before purchasing.

Telehealth platform: Growing number of platforms provide physician consultation, prescription, and peptide delivery in one package. Convenient but costs $150-$300/month including the consultation fee.

Regardless of source, verify: independent third-party purity testing (not just in-house), HPLC or mass spectrometry analysis, sterile compounding certification for injectables. The best peptide vendors page covers what to check.

Compoundable by prescription, still not approved.

As of November 2026, BPC-157 is not FDA-approved for any therapeutic indication. On July 23, 2026, FDA's advisory committee voted 8–6 with 1 abstention to recommend it for the 503A bulks list. On October 28, 2026, HHS issued an interim policy under which it will not take enforcement action against state-licensed pharmacies, federal facilities or licensed physicians that compound single-ingredient BPC-157 acetate for subcutaneous, intramuscular, oral or topical use with a patient-specific prescription (Federal Register, October 30, 2026, 91 FR 68526). Blends such as BPC-157 + TB-500 are not covered. FDA rulemaking to add BPC-157 to the bulks list is still pending, and HHS can revisit the policy.

In practice: BPC-157 is legal to prescribe and legal to compound as a single ingredient under the policy's conditions, and legal to possess for personal use in the United States. Vials sold online with "laboratory use" labels sit outside the policy. Details: what the HHS peptide policy says and how the July 2026 FDA vote went.

Frequently Asked Questions

What is BPC-157?
BPC-157 is a 15-amino acid peptide derived from a protein found in human gastric juice. It accelerates healing across tendons, ligaments, muscles, gut lining, nerves, and skin by promoting angiogenesis (new blood vessel formation), upregulating growth factors, and reducing inflammation. It's the most widely used healing peptide, available through compounding pharmacies and licensed peptide suppliers.
What does BPC-157 do?
BPC-157 builds new blood vessels at injury sites, increases growth factor activity, modulates nitric oxide signaling, and reduces inflammatory cytokines. This accelerates healing of tendons, ligaments, gut lining, muscles, nerves, and skin. The most commonly reported effects are faster tendon/joint recovery, gut symptom relief, and reduced inflammation.
How long does BPC-157 take to work?
Gut benefits often appear within 3 to 7 days. Tendon and joint pain typically improves within 1 to 2 weeks. Muscle recovery benefits appear within 1 to 2 weeks. Full structural healing of injuries takes 4 to 8 weeks. Nerve healing is slowest at 8 to 12 weeks.
Is BPC-157 safe?
BPC-157 has an excellent safety profile based on extensive community use. Side effects are mild: injection site redness, occasional nausea. No serious adverse events have been widely reported at standard doses (250-500 mcg/day), and the three published human pilots (30 people in total) reported no treatment-related adverse events, though they were far too small to detect rare harms. People with active cancer should consult their oncologist due to the angiogenic mechanism. The peptide is derived from a protein your body naturally produces in gastric juice.
Should I inject BPC-157 or take it orally?
For gut-specific issues (IBS, leaky gut, NSAID damage), oral capsules deliver directly to the GI tract and are effective. For tendon, joint, muscle, or systemic benefits, subcutaneous injection provides higher bioavailability and systemic distribution. Some people use injection for the initial healing phase, then switch to oral for maintenance.
Can BPC-157 heal old injuries?
Yes. BPC-157 is frequently used for chronic injuries that haven't resolved. The angiogenic effect creates new blood supply to tissue that has been under-perfused since the original injury, restarting the healing process. Tendon pain from injuries months or years old often responds within 2 to 4 weeks. Results are better for chronic tendon/ligament issues than for complete structural tears.
Is BPC-157 better with TB-500?
Many people stack them (the Wolverine Stack) because BPC-157 builds blood vessels (angiogenesis) while TB-500 promotes cell migration, two different healing bottlenecks. The evidence for "better together" is thin, though: the only direct comparison, a 2026 Achilles tendon study in lab animals (Biçer et al., PMID 42542926), found the combination added no benefit over either peptide alone, and TB-500 alone gave the clearest gains. No human study has tested the stack.
Is BPC-157 legal?
Yes, with limits. As of November 2026, BPC-157 is legal to prescribe and to possess for personal use in the United States, and since October 28, 2026 an interim HHS policy lets 503A pharmacies compound single-ingredient BPC-157 (injection, oral or topical) with a patient-specific prescription. Blends with TB-500 are not covered. It is still not FDA-approved for any indication, and it is banned in tested sport (WADA S2).
What is the best BPC-157 dosage?
The standard protocol is 250-500 mcg once daily via subcutaneous injection for 4 to 8 weeks. For acute injuries, 500 mcg twice daily for 2 to 4 weeks. For oral use (gut goals), 500-1,000 mcg daily. Start at 250 mcg and increase if needed. Cycle 4-8 weeks on, 2-4 weeks off. Our dosage guide uses 250 mcg twice daily as its standard; both are community conventions, not trial doses.
What happened at the July 2026 FDA meeting on BPC-157?
On July 23, 2026, FDA's Pharmacy Compounding Advisory Committee voted 8–6 with 1 abstention to recommend adding BPC-157 to the 503A bulks list, the list of substances pharmacies may compound from. FDA staff had recommended against it, and the vote is advisory. On October 28, 2026, HHS followed with an interim policy allowing prescription compounding of single-ingredient BPC-157 while FDA rulemaking continues.
What is the half-life of BPC-157?
Under 30 minutes. The only published pharmacokinetic study measured an elimination half-life of the intact peptide of less than 30 minutes after intravenous or intramuscular dosing (He et al., Front Pharmacol 2022, PMID 36588717). There is no published human half-life. The short half-life is why many protocols split the daily dose into two injections.

Sources

  • He L, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157. Front Pharmacol. 2022;13:1026182. PMID 36588717
  • Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021;27(4):8-13. PMID 34324435
  • Lee E, Walker C, Ayadi B. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024;30(10):12-17. PMID 39325560
  • Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025;31(5):20-24. PMID 40131143
  • Poolton JT, et al. Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review. Acta Orthop Belg. 2026;92(3). PMID 42885452
  • Biçer O, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing. Jt Dis Relat Surg. 2026;37(3):822-837. PMID 42542926
  • U.S. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 list; content current as of April 22, 2026). fda.gov
  • HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register, October 30, 2026 (91 FR 68526). federalregister.gov; AJMC. HHS draft policy eases enforcement on 6 compounded peptides (October 29, 2026). ajmc.com
  • RAPS. FDA advisory committee backs two controversial peptides (July 23, 2026). raps.org

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. BPC-157 has not been evaluated by the FDA for any therapeutic use. Individual results vary. Consult a licensed healthcare provider before starting any peptide protocol.

BPC-157 (10mg)

Recommended Supplier

In StockShips from USA

BPC-157 (10mg)

BPC-157 (10mg) from Ascension Peptides, third-party tested and shipped from the US.

$24.50$49.00Save $24.50

Exclusive 50% off — use code PEPTIDEDECK

Buy Related Peptides — 99%+ Purity

BPC-157

BPC-157

10mg Single Vial · 99%+ Purity

From $49.00
Wolverine Stack

Wolverine Stack

20mg Blend Vial · 99%+ Purity

From $90.00
TB-500

TB-500

5mg Single Vial · 99%+ Purity

From $54.00

Related Topics

BPC-157peptideshealingtendongut healthTB-500Wolverine Stack
BPC-157 (10mg)

save 50% with code

Get 50% Off